Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 14/20 | 0.71 |
| ▸ | CTSL | P07711 | 6/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5906582 | 1.00 | CTSC (0.71) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL5564472 | 0.86 | CTSC (0.70) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL5564477 | 0.86 | CTSC (0.70) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL3499841 | 0.86 | CTSC (0.59) | CTSCCTSLCTSKCTSS | |
| SCHEMBL20397730 | 0.85 | CTSC (0.64) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL10961618 | 0.85 | CTSL (0.70) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL15254330 | 0.85 | CTSC (0.55) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL2074452 | 0.85 | CTSC (0.55) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL18262589 | 0.85 | CTSC (0.54) | CTSCCTSLCTSKCYP1A2CYP3A4 | |
| SCHEMBL20397731 | 0.85 | CTSC (0.64) | CTSCCTSLCTSKCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | MERCK FROSST CANADA LTD. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264479-A1 | Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases | CTSL, CSTB, PREP | CTSC 23/4885CTSL 1/4885CTSK 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.